Maky Zanganeh

Maky Zanganeh, DDS, has served as Summit’s Co-Chief Executive Officer & President since July 2022, having previously served as our Chief Operating Officer since joining Team Summit in November 2020. She is also a member of the Board of Directors

She has more than 15 years of management, corporate, clinical, and business experience in the pharmaceutical, medical device, and technology industries.

Most recently, Dr. Zanganeh is the Founder & CEO of Maky Zanganeh and Associates (“MZA”). Prior to starting and leading MZA in 2015, Dr. Zanganeh held multiple leadership positions at Pharmacyclics, Inc., from 2008 to 2015, culminating in her role as Chief Operating Officer, where she oversaw all clinical, research, commercial, and business-related matters. Dr. Zanganeh played a key role both in the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Janssen Biotech, Inc. in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015. The acquisition of Pharmacyclics by AbbVie remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.

Previously, she held senior positions of increasing responsibility within companies such as Robert Duggan & Associates, a private investment firm, and Computer Motion, Inc., a pioneer in robotic surgery.

Dr. Zanganeh earned FierceBiotech’s “Top Women in Biotech” award in 2013. She received her DDS from Louis Pasteur University (France) and her MBA from Schiller International University (France).

Beyond Summit, Dr. Zanganeh is currently a board member for Pulse Biosciences, Inc., as well as her role as the Founder & CEO of MZA.